Статья
МАГНИЙ В КЛИНИЧЕСКОЙ ПРАКТИКЕ
Магний относится к макроэлементам, необходимым для нормальной жизнедеятельности организма. Дефицит магния, возникающий в результате влияния экзогенных и эндогенных факторов, диагностируют по клиническим проявлениям, напоминающим известные болезни. Коррекцию дефицита магния проводят препаратами магния. Исследования показывают эффективность оротата магния при многих сердечно-сосудистых заболеваниях.
1. Swaminathan R. Magnesium Metabolism and its Disorders. Clin Biochem Rev 2003;24 (2):47–66.
2. Saris N.E., Mervaala E., Karppanen H., Khawaja J.A., Lewenstam A. Magnesium. An update on physiological, clinical and analytical aspects. Clin Chim Acta 2000;294:1–26.
3. Ryan M.F ., Barbour H. Magnesium measurement in routine clinical practice. Ann Clin Biochem 1998;35:449–459.
4. Rude R.K. Magnesium metabolism and deficiency. Endocrinol Metab Clin North Am 1993; 22: 377–395.
5. Wu A. Tietz Clinical Guide to Laboratory Tests. 4th Ed. St. Louis, MO: Saunders Elsevier; 2006
6. Bardicef M., Bardicef O., Sorokin Y ., et al. Extracellular and intra-cellular magnesium depletion in pregnancy and gestational diabetes. Am J Obstet Gynecol 1995;172:1009–1013.
7. Gonzalez-Revalderia J., Garcia-Bermejo S., Menchen-Herreros A., Fernandez-Rodriguez E. Biological variation of Zn, Cu, and Mg in serum of healthy subjects. Clin Chem 1990;36:2140–2141.
8. Whang R., Oei T.O., Aikawa J.K., et al. Predictors of clinical hypomagnesemia. Hypokalemia, hypophosphatemia, hyponatremia, and hypocalcemia. Arch Intern Med 1984; 4: 794–1796.
9. Fox C., Ramsoomair D., Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001;94:1195–1201.
10. Wong E.T., Rude R.K., Singer F .R., Shaw S.T. A high prevalence of hypomagnesemia and hypermagnesemia in hospitalised patients.Am J Clin Pathol 1983;79:348–355.
11. Hayes J.P ., Ryan M.F ., Brazil N. et al. Serum hypomagnesaemia in an elderly day-hospital population. Ir Med J 1989;82:117–121.
12. Naderi A.S.A., Reilly R. F . Jr . Hereditary etiologies of hypomagnesemia. Nature Clinical Practice Nephrology 2008;4:80–89.
13. Konrad M., Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 2003;14:249–260.
14. Schlingmann K.P ., Konrad M., Seyberth H.W. Genetics of hereditary disorders of magnesium homeostasis. Pediatr Nephrol 2004;19:13–25.
15. Kadurina TI, Gorbunova, VN. Connective tissue dysplasia. St. Petersburg: ELBI-SPb; 2009. Russian (Кадурина Т . И., Г орбунова В. Н. Дисплазия соединительной ткани. СПб: ЭЛБИ-СПб; 2009).
16. National guidelines for hereditary disorders of connective tissue. Kardiovaskuljarnaja terapija i profilaktika 2009; 8(6) suppl 5: 1–24. Russian (Национальные рекомендации по наследственным нарушениям соединительной ткани. Кардиоваскулярная терапия и профилактика 2009; 8(6) Приложение 5: 1–24).
17. Fawcett W.J., Haxby E.J., Male D.A. Magnesium: physiology and pharmacology. Br J Anaesth 1999;83:302–320.
18. Ryzen E., Rude R.K. Low intracellular magnesium in patients with acute pancreatitis and hypocalcemia. West J Med 1990;152:145–148.
19. Satur C.M., Stubington S.R., Jennings A., et al. Magnesium flux during and after open heart operations in children. Ann Thorac Surg 1995;59:921–927.
20. al-Ghamdi S.M., Cameron E.C., Sut ton R.A. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1994;24:737–752.
21. Torralbo A., Portoles .J, Perez A.J., Barrientos A. Hypomagnesemic hypocalcemia in chronic renal failure. Am J Kidney Dis 1993;21:167–171.
22. Tattersall J.E., Dick C., Doyle S., et al. Alkalosis and hypomagnesaemia: unwanted effects of a low-calcium CAPD solution. Nephrol Dial Transplant 1995;10:258–262.
23. Elin R.J., Hosseini J.M., Fitzpatrick L., et al. Blood magnesium status of patients with parathyroid disease. Magnes Tr Ele 1990;9:119–123.
24. Chaudhary D.P ., Sharma R., Bansal D.D . Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 2010;134(2):119–29.
25. Tosiello L. Hypomagnesemia and diabetes mellitus. Arch Intern Med 1996;156:1143–1148.
26. de Valk V.H. Magnesium in diabetes mellitus. Neth J Med 1999;54:139–146.
27. Dorup I. Magnesium and potassium deficiency. Its diagnosis, occurrence and treatment in diuretic therapy and its consequences for growth, protein synthesis and growth factors. Acta Physiol Scand Suppl 1994;618:1–55.
28. Markmann M., Rothman R., Reichman B., et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer . J Cancer Res Clin Oncol 1991;117:89–90.
29. Koch N.P ., Hadj-Aissa A., Schell M., et al. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephro 1998;12:572–575.
30. Elliott C, Newman N, Madan A. Gentamicin effects on urinary electrolyte excretion in healthy subjects. Clin Pharmacol Ther 2000;67:16–21.
31. Knutsen R., Bohmer T., Falch J. Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks. Scand J Clin Lab Inves 1994;54:119–125.
32. Haffner C.A., Kendall M.J. Metabolic effects of beta 2-agonists. J Clin Pharm Ther 1992;17:155–164.
33. Nijenhuis T ., Hoenderop J.G., Bindels R.J. Downregulation of Ca2+ and Mg2+ transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004;15:549–557.
34. Sheen E., Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Digestive diseases and sciences 2011;56(4):931–950.
35. Huang C.L., Kuo E. Mechanism of Hypokalemia in Magnesium Deficiency. J Am Soc Nephrol 2007;18(10):2649–2652.
36. Fox C., Ramsoomair D., Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001;94:1195–1201.
37. Nadler J.L., Rude R.K. Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 1995;24:623–641.
38. Nozue T ., Kobayashi A., Uemasu F ., et al. Magnesium status, serum HDL cholesterol, and apolipoprotein A-1 levels. J Pediatr Gastroenterol Nutr 1995;20:316–318.
39. Shechter M., Sharir M., Labrador M.J. et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102:2353–2358.
40. Liao F ., Folsom A.R., Brancati F .L. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998;136(3):480–490.
41. Ueshima K. Magnesium and ischemic heart disease: a review of epidemiological, experimental, and clinical evidences. Magnes Res 2005;18(4):275–284.
42. Rutherford P .A, Thomas T .H., Wilkinson R. Increased erythrocyte sodium-lithium counter transport activity in essential hypertension is due to an increased af finity for extracellular sodium. Clin Sci 1990;79:365–369.
43. Shechter M. Does magnesium have a role in the treatment of patients with coronary artery disease? Am J Cardiovasc Drugs 2003;3(4):231–239.
44. Viskin S. Torsades de Pointes. Curr Treat Options Cardiovasc Med 1999;1(2):187–195.
45. Viskin S., Fish R. Prevention of ventricular arrhythmias in the congenital long QT syndrome. Curr Cardiol Rep 2000;2(6):492–497.
46. Tosiello L. Hypomagnesemia and diabetes mellitus. Arch Intern Med 1996;156:1143–1148.
47. Zabelina V.D. Magnesium and magnesium-containing drugs. With magnesium for life. Consilium-provisorum 2003;3(5): 27–30. Russian (Забелина В.Д. Магний и магнийсодержащие препараты. С магнием по жизни. Consilium-provisorum 2003;3(5): 27–30.
48. Stepura O.B., Ostroumova O.D. Use of oral magnesium preparations for the treatment of cardiovascular diseases. Russkij Medicinskij Zhurnal 2010;3(18):109–112. Russian (Степура О.Б., Остроумова О.Д. Применение пероральных препаратов магния для лечения сердечно-сосудистых заболеваний. РМЖ 2010;3(18):109–112).
49. Zehender M., Meinertz T ., Faber T ., et al. Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. J Am Coll Cardiol 1997;29:1028–1034.
50. Davey M.J., Teubner D.A. Randomized controlled trial of magnesium sulfate in addition to usual care, for rate control in atrial fibrillation. Annals of Emergency Medicine 2005;45:347–353.
51. Davidova C., Yarovoiy C. Preparations of magnesium in the treatment and prevention of supraventricular tachyarrhythmias in patients with urological profile. Vrach 2011;(9):44–49. Russian (Давыдова С., Яровой С. Препараты магния в лечении и профилактике суправентрикулярных тахиаритмий у больных урологического профиля. Врач 2011;(9):44–49).
52. Chilov A.M., Galanova A.C., Griasnov D.A. et al. Metabolic syndrome and magnesium deficiency: characteristics of the course and treatment. Vrach 2008;(9):44–48). Russian (Шилов А.М., Г аланова А.С., Г рязнов Д.А. и др. Метаболический синдром и дефицит магния: особенности течения и лечения. Врач 2008;(9):44–48).
53. Martinov A.I., Akatova E.V. The experience of fifteen years of preparations of magnesium in patients with mitral valve prolapse. Kardiologiia 2011;(6):60–65. Russian (Мартынов А.И., Акатова Е.В. Опыт пятнадцатилетнего применения препаратов магния у больных с пролапсом митрального клапана. Кардиология 2011;(6):60–65).
54. Martinov A.I., Akatova E.V., Nikolin O.P ., The effectiveness of the drug "Magnerot®» syndrome with manifestations of vascular disorders, and hemorrhagic syndrome in patients with idiopathic mitral valve prolapse. Consilium medicum, CardioSomatika 2011; 1:13–17. Russian (Мартынов А.И., Акатова Е.В., Николин О.П. Эффективность применения препарата «Магнерот®» при проявлениях синдрома сосудистых нарушений и геморрагического синдрома у больных с идиопатическим пролапсом митрального клапана. CardioСоматика 2011; 1:13–17.
55. Pak L.C. The value of magnesium in the pathogenesis and treatment of patients with mitral valve prolapse. Trudniy pacient 2007;5(5): 13–6. Russian (Пак Л.С. Значение магния в патогенезе и лечении больных пролапсом митрального клапана. Трудный пациент 2007;5(5): 13–6.